TaiGen Biopharmaceuticals Holdings Ltd (太景醫藥研發控股) on Monday said it would start selling the injectable formulation of its novel antibiotic Taigexyn in China next year after the manufacturer passed the Chinese regulators’ on-site inspection.
The Chinese National Medical Products Administration’s Center for Drug Evaluation began its inspection at Zhejiang Medicine Co Ltd’s (ZMC, 浙江醫藥) factory on Friday.
The Chinese pharmaceutical firm, a partner of TaiGen’s unit in Beijing, is to manufacture and market the injectable antibiotic in China.
The center finished its inspection yesterday, announcing that it had found no major errors after it examined the equipment, production process, quality control program, the ingredients and tested some samples, TaiGen said in a statement.
The center “gave us some suggestions to tweak production. Overall, it can be said that the factory passed the inspection,” TaiGen communication manager Grace Wang (王暄茹) said by telephone.
As on-site inspections marks the final stage of new drug application in China, the company is expected to receive marketing approval soon and launch sales next year, Wang said.
The approval would enable TaiGen to expand its Taigexyn production line, offering doctors an option besides the oral version of Taigexyn that it began selling in 2016, she said.
“We found that doctors prefer prescribing the oral versions of antibiotics for patients with less severe symptoms, as they can take the tablets themselves,” Wang said.
The injectable version of Taigexyn is forecast to be used for inpatient treatment or for patients with severe symptoms, she said.
The sales of oral Taigenxyn in Taiwan in the first nine months of the year surged 250 percent from a year earlier, while making an annual gain of 170 percent in China, the company’s data showed.
Sales of injectable version are expected to generate higher profits, as its price would be at least eight times more than the tablets, Wang said.
As it might take some time for the new drug to be included in China’s public health insurance program, Chinese might have to pay for the drug themselves, she added.
TaiGen said it is also seeking market approval for the intravenous formulation from Taiwan’s Food and Drug Administration and submitted a new drug application on Oct. 16.
It is difficult to forecast how long the agency’s review will take, the company said.
TaiGen shares yesterday fell 0.81 percent to NT$18.35 in Taipei trading. They have risen 7.94 percent this year.
BUSINESS UPDATE: The iPhone assembler said operations outlook is expected to show quarter-on-quarter and year-on-year growth for the second quarter Hon Hai Precision Industry Co (鴻海精密) yesterday reported strong growth in sales last month, potentially raising expectations for iPhone sales while artificial intelligence (AI)-related business booms. The company, which assembles the majority of Apple Inc’s smartphones, reported a 19.03 percent rise in monthly sales to NT$510.9 billion (US$15.78 billion), from NT$429.22 billion in the same period last year. On a monthly basis, sales rose 14.16 percent, it said. The company in a statement said that last month’s revenue was a record-breaking April performance. Hon Hai, known also as Foxconn Technology Group (富士康科技集團), assembles most iPhones, but the company is diversifying its business to
ARTIFICIAL INTELLIGENCE: The chipmaker last month raised its capital spending by 28 percent for this year to NT$32 billion from a previous estimate of NT$25 billion Contract chipmaker Powerchip Semiconductor Manufacturing Corp (力積電子) yesterday launched a new 12-inch fab, tapping into advanced chip-on-wafer-on-substrate (CoWoS) packaging technology to support rising demand for artificial intelligence (AI) devices. Powerchip is to offer interposers, one of three parts in CoWoS packaging technology, with shipments scheduled for the second half of this year, Powerchip chairman Frank Huang (黃崇仁) told reporters on the sidelines of a fab inauguration ceremony in the Tongluo Science Park (銅鑼科學園區) in Miaoli County yesterday. “We are working with customers to supply CoWoS-related business, utilizing part of this new fab’s capacity,” Huang said, adding that Powerchip intended to bridge
Qualcomm Inc, the world’s biggest seller of smartphone processors, gave an upbeat forecast for sales and profit in the current period, suggesting demand for handsets is increasing after a two-year slump. Revenue in the three months ended in June will be US$8.8 billion to US$9.6 billion, the company said in a statement Wednesday. Excluding certain items, earnings will be US$2.15 to US$2.35 a share. Analysts had projected sales of US$9.08 billion and earnings of US$2.16 a share. The outlook signals that the smartphone market has begun to bounce back, tracking with Qualcomm’s forecast that demand would gradually recover this year. The San
Clambering hand-over-hand, sweat dripping into his eyes, a durian laborer expertly slices a cumbersome fruit from a tree before tossing it down to land with a soft thump in his colleague’s waiting arms about 15m below. Among Thailand’s most famous and lucrative exports, the pungent “king of fruits” is as distinctive in its smell as its spiky green-brown carapace, and has been farmed in the kingdom for hundreds of years. However, a vicious heat wave engulfing Southeast Asia has resulted in smaller yields and spiraling costs, with growers and sellers increasingly panicked as global warming damages the industry. “This year is a crisis,”